HomeCompareITOS vs PM

ITOS vs PM: Dividend Comparison 2026

ITOS yields 19.70% · PM yields 3.49%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ITOS wins by $22.1K in total portfolio value
10 years
ITOS
ITOS
● Live price
19.70%
Share price
$10.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$71.7K
Annual income
$6,528.88
Full ITOS calculator →
PM
Philip Morris International
● Live price
3.49%
Share price
$164.83
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,502.61
Full PM calculator →

Portfolio growth — ITOS vs PM

📍 ITOS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodITOSPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ITOS + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ITOS pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ITOS
Annual income on $10K today (after 15% tax)
$1,674.88/yr
After 10yr DRIP, annual income (after tax)
$5,549.55/yr
PM
Annual income on $10K today (after 15% tax)
$297.03/yr
After 10yr DRIP, annual income (after tax)
$2,127.22/yr
At 15% tax rate, ITOS beats the other by $3,422.33/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ITOS + PM for your $10,000?

ITOS: 50%PM: 50%
100% PM50/50100% ITOS
Portfolio after 10yr
$60.7K
Annual income
$4,515.75/yr
Blended yield
7.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

ITOS
Analyst Ratings
3
Buy
5
Hold
Consensus: Hold
Price Target
$18.20
+79.3% upside vs current
Range: $9.00 — $46.00
Altman Z
1.6
Piotroski
1/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.9% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ITOS buys
0
PM buys
0
No recent congressional trades found for ITOS or PM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricITOSPM
Forward yield19.70%3.49%
Annual dividend / share$2.00$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17.2%
Portfolio after 10y$71.7K$49.6K
Annual income after 10y$6,528.88$2,502.61
Total dividends collected$40.5K$11.8K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy
Analyst price target$18.20$194.30

Year-by-year: ITOS vs PM ($10,000, DRIP)

YearITOS PortfolioITOS Income/yrPM PortfolioPM Income/yrGap
1← crossover$12,670$1,970.44$11,650$409.56+$1.0KITOS
2$15,891$2,333.31$13,592$497.49+$2.3KITOS
3$19,738$2,734.88$15,882$605.21+$3.9KITOS
4$24,294$3,174.78$18,589$737.41+$5.7KITOS
5$29,647$3,652.03$21,794$899.94+$7.9KITOS
6$35,887$4,165.10$25,597$1,100.16+$10.3KITOS
7$43,111$4,711.97$30,118$1,347.30+$13.0KITOS
8$51,419$5,290.18$35,505$1,652.97+$15.9KITOS
9$60,916$5,896.86$41,940$2,031.88+$19.0KITOS
10$71,709$6,528.88$49,643$2,502.61+$22.1KITOS

ITOS vs PM: Complete Analysis 2026

ITOSStock

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Full ITOS Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this ITOS vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ITOS vs SCHDITOS vs JEPIITOS vs OITOS vs KOITOS vs MAINITOS vs MOITOS vs BTIITOS vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.